Phase 2 Trial Targets Increased Hydroxyurea Dosages to Curb Strokes in Children with Sickle Cell Disease
A Phase 2 clinical trial, aiming to assess the effects of hydroxyurea-based therapy at the maximum tolerated dose to prevent stroke in children with sickle cell anemia (SCA), began recently, and the outcomes are expected to highly impact children worldwide, particularly those living in developing countries where the disease is…